Lapatinib and tastuzumab for HER+ colorectal cancer – pro
There is evidence to support HER based therapy from the phase II HERACLES-A study that used meticulous biomarker selection of patients with HER2-amplified colorectal cancer, who typically do not respond well to conventional treatment options A two-pronged strategy, with lapatinib and trastuzumab yielded positive results in this subset of patients. Lapatinib plus trastuzumab is a potential new treatment option for treatment-refractory HER2-positive
Read more